Drug class
Dipeptidyl-Peptidase IV Inhibitors clinical trials
A class of medicines: the studies that test any of its 20 members, each study once. Members are as MeSH files each medicine’s actions, and as the NCI Thesaurus classes newer ones.
Keep track of what changes. Save the dipeptidyl-peptidase iv inhibitors studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesMedicines in this class
Studies that test each. A study of two counts under both, and once above.
- Cofrogliptin
- 2
- Carmegliptin
- 1
- Bisegliptin
- 1
- Denagliptin
- 1
Studies by the year they started
897 studies that test it; most in 2008 (78)
| Year | Studies |
|---|---|
| 2003 | 3 |
| 2004 | 25 |
| 2005 | 30 |
| 2006 | 48 |
| 2007 | 39 |
| 2008 | 78 |
| 2009 | 73 |
| 2010 | 76 |
| 2011 | 47 |
| 2012 | 64 |
| 2013 | 70 |
| 2014 | 63 |
| 2015 | 50 |
| 2016 | 55 |
| 2017 | 27 |
| 2018 | 18 |
| 2019 | 23 |
| 2020 | 27 |
| 2021 | 18 |
| 2022 | 10 |
| 2023 | 13 |
| 2024 | 13 |
| 2025 | 13 |
| 2026 | 14 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 553 · Other 346
Merck Sharp & Dohme LLC (93) · Boehringer Ingelheim (76) · AstraZeneca (63) · Novartis Pharmaceuticals (49) · Takeda (47) · Novartis (43) · LG Life Sciences (18) · Jiangsu HengRui Medicine Co., Ltd. (17)
Studies
Open first, then newest update. How each study uses a medicine is read from its arms, and is right about nine times in ten.
Testing one of them · 899
- Comparative Study Between (SGLT-2i) and (DPP-4i) in the Prevention of DICRecruitingPhase 4Tanta UniversityNCT07436663Written as Sitagliptin (DPP4 inhibitor)
- Pre-diabetes in Subject With Impaired Fasting Glucose (IFG) and Impaired Glucose Tolerance (IGT)RecruitingNot applicableThe University of Texas Health Science Center at San AntonioNCT02969798Written as Saxagliptin
- Efficacy of Vildagliptin Versus Metformin in Patients With Polycystic Ovary SyndromeNot yet recruitingPhase 2/3Tanta UniversityNCT07811011Written as Vildagliptin (Galvus)
- Disease-modifying Efficacy of Sitagliptin Therapy in Early-stage Parkinson's DiseaseNot yet recruitingPhase 2Yonsei UniversityNCT07804381Written as Sitagliptin
- A Phase 2 and Pharmacodynamic Study of Sitagliptin in Patients With Progressive Grade 4 GliomasRecruitingPhase 2Case Comprehensive Cancer CenterNCT07003542Written as Sitagliptin
- Sitagliptin With Pembro in RCC and MelanomaRecruitingPhase 1Fernando Maciel BarbosaNCT07634380Written as Sitagliptin
- Sun Yat-Sen Treatment Strategy for Enhancing Response in Muscle-invasive Bladder CancerRecruitingPhase 2Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityNCT07717242Written as Sitagliptin
- Sitagliptin in Recurrent/Progressive Grade 4 GliomaRecruitingPhase 1Kailin Yang, MD, PhDNCT07541781Written as Sitagliptin
- Neoadjuvant Chemotherapy, Anti-PD-1 Antibody and Sitagliptin for Locally Advanced pMMR CRCRecruitingPhase 1/2Second Affiliated Hospital, School of Medicine, Zhejiang UniversityNCT07365592Written as Sitagliptin (DPP4 inhibitor)
- Effects of Cofrogliptin on Beta-Cell Function in LADA PatientsNot yet recruitingNot applicableSecond Xiangya Hospital of Central South UniversityNCT07460336Written as Cofrogliptin
- Glycemic Control With Triple Pathway Approach Through Empagliflozin, Linagliptin and Metformin CombinationRecruitingPhase 4Nabiqasim Industries (Pvt) LtdNCT06862739Written as Empagliflozin+Linagliptin+Metformin
- Metformin, Empagliflozin With Sitagliptin vs Linagliptin in Type 2 DiabetesEnrolling by invitationPhase 4Bahria UniversityNCT07452913Written as Metformin+ Empagliflozin + Sitagliptin
- Glycemic Variability of Combination Therapies in T2DMRecruitingPhase 4JW PharmaceuticalNCT07442006Written as Anagliptin
- A Multicenter, Randomized, Open-Label, Parallel-Controlled Clinical Study Comparing the Efficacy and Safety of Cofrogliptin Versus Acarbose in Drug-Naïve Patients With Type 2 DiabetesNot yet recruitingNot applicableHaisco Pharmaceutical Group Co., Ltd.NCT07122102Written as Cofrogliptin
- Effect of Add-on SGLT2i, TZD, or Combination Therapy in Type 2 Diabetes Patients on DPP4 InhibitorsNot yet recruitingPhase 4Yonsei UniversityNCT07108985Written as Sitagliptin 100 mg
- Efficacy of Vildagliptin Versus Metformin in Poly Cystic Ovary SyndromeRecruitingPhase 2/3October 6 UniversityNCT06142656Written as Vildagliptin 50 MG
- Comparison Between Efficacy of Trelagliptin and Sitagliptin in Type II Diabetic PatientsEnrolling by invitationPhase 3Khyber Medical College, PeshawarNCT07073768Written as Trelagliptin 100 mg
- Clinical Trial of Vildagliptin in Early Parkinson's DiseaseNot yet recruitingNot applicableFirst Affiliated Hospital, Sun Yat-Sen UniversityNCT06951334Written as Vildagliptin 50 mg bid
- Sitagliptin or BeiDouGen Capsule Improve the Pregnancy Outcome in Patients with PCOSRecruitingNot applicablePeking University Third HospitalNCT06587698Written as Sitagliptin
- Real-World Evaluation of Omarigliptin for Type 2 Diabetes Meliitus in BangladeshNot yet recruitingPhase 4Bangladesh Institute of Research and Rehabilitation in Diabetes, Endocrine and Metabolic DisordersNCT06449235Written as Omarigliptin
See all 899 studies that test one of the dipeptidyl-peptidase iv inhibitors →
Codes
What other systems call Dipeptidyl-Peptidase IV Inhibitors · ClinicalTrials.gg INT008910
- MeSH (NLM) D054873Dipeptidyl-Peptidase IV InhibitorsOne source ClinicalTrials.gov
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | D054873 | Dipeptidyl-Peptidase IV Inhibitors | One source ClinicalTrials.gov |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.